CryoEase-PF – A DMSO-Free, Protein-Free Cryopreservation Media for MSCs & Sensitive Cells

Dual-Temperature Compatible. Validated Performance. Translationally Ready.

CryoEase-PF is a next-generation, DMSO-free and protein-free cryopreservation medium designed specifically for the long-term preservation and short-term stability of human mesenchymal stem cells (MSCs) and other sensitive cell types.

What sets CryoEase-PF apart is its dual-temperature compatibility—the only cryomedia designed for both long-term storage in vapor-phase liquid nitrogen (-150°C) and short-term stability at 4°C for up to 72 hours. This breakthrough formulation enables real-world transport, decentralized trial execution, and cold chain simplification, ensuring your cells remain viable and functional — from cryobank to bedside.
Engineered in Singapore by AGEMBio, a cell therapy innovator, CryoEase-PF is optimized to meet the demands of biobanking, global cell therapy trials, and translational research workflows.

With >85% post-thaw viability and full ISCT-compliant phenotype retention even after 72 hours of hypothermic storage, CryoEase-PF provides unmatched protection for MSCs—from cryobank to bedside.

Validated Performance

• >85% Viability After 72 Hours at 4°C
  Outperforms commercial cryomedia with <75% viability in the same conditions
• 23-Hour Population Doubling Time Post-Thaw
  Comparable to fresh MSCs
• 30-Hour PDT After 72h Hypothermic Hold
  Ensures reliable cell expansion after transportation delays
• ISCT-Compliant MSC Identity
  Retains CD73+/CD90+/CD105+ and CD34-/CD45-/HLA-DR- phenotype

Validation conducted using human adipose-derived MSCs (5 x 10⁶ cells/mL) stored at -150°C and held at 4°C for 72h post-thaw. Viability assessed via 7AAD staining.

Dual-Temperature Compatibility: Real-World Ready

CryoEase-PF is uniquely optimized for translational logistics and multi-site trial workflows, allowing:

• Long-Term Biobanking: Vapor-phase LN₂ storage (-150°C)
• Short-Term Transport Stability: Maintains viability at 4°C for 72h
• Cold Chain Flexibility: Reduce reliance of dry ice and liquid nitrogen
• Allogeneic & Autologous Ready: Supports scalable, GMP workflows

This dual-temperature stability is unmatched in DMSO-free, protein-free cryopreservation — making CryoEase-PF the only truly translational-ready solution on the market.

Engineered for Translational Success

CryoEase-PF is formulated to support both allogeneic and autologous MSC workflows, ensuring functional and phenotypic consistency critical to IND filings, EMA submissions, and global trial logistics.

• Trilineage Differentiation Maintained – Osteogenic, chondrogenic, adipogenic
• Batch-to-Batch Consistency – Pre-mixed, endotoxin-tested
• No DMSO, No Proteins, No Risk – Eliminates toxicity concerns from cryoprotectants

Built for Global Deployment

Dual-temperature compatibility enables CryoEase-PF to simplify global logistics:

• Long-term: Storage in vapor-phase LN₂ (-150°C)
• Short-term: Viability at 4°C for up to 72 hours — ideal for multi-site advanced research studies and regional cell transport

CryoEase-PF vs. Conventional Cryomedia

Applications in MSC-Based Therapies

CryoEase-PF is engineered to meet the needs of every frontline advancing stem cell innovation:

• Clinical Settings:
  Support MSC-based therapies with predictable and reproducible outcomes, critical for ensuring patient safety and therapeutic success.
• Biobanking:
  Preserve high-quality stem cells for long-term storage while maintaining viability and potency, ensuring reliable downstream applications.
• Research Laboratories:
  Enable robust, repeatable experiments by safeguarding stem cell integrity during cryopreservation and recovery.
• Veterinary Medicine:
  Facilitate advanced stem cell applications in animal health with DMSO-free, protein-free preservation optimized for sensitive cell types.

Developed by AGEMBio – Distributed by Atlantis Bioscience

CryoEase-PF is developed by AGEMBio, an NUS spin-off backed by SGInnovate, with a mission to redefine stem cell therapy through
immune-activating MSC platforms.

As exclusive distributor, Atlantis Bioscience supports the deployment of CryoEase-PF across APAC and beyond—aligning with our vision to deliver bench-to-bedside solutions that enable life-saving research, clinical translation, and scalable biomanufacturing.

Collaborate With Us – Expand CryoEase-PF to Your Cell Type

We’re inviting researchers and developers worldwide to explore CryoEase-PF’s capabilities across new cell types:

• ✓ Pilot studies with complimentary samples
• ✓ Collaborative method development
• ✓ Custom formulation support for sensitive cell lines

Contact us to join the validation network:

email: [email protected]
website: www.atlantisbioscience.com/contact-us/